Aspire Biopharma Holdings (ASBP) Cash & Equivalents Growth (1y) (2023 - 2026)
Powered by 
Analysis
Aspire Biopharma Holdings (ASBP) Cash & Equivalents Growth (1y) (2023 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 74.25% |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | -38.20% |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 23.56% |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 23.05% |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | 34.71% |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 71.81% |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 53.39% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | -53.42% |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | - |
| 10 | Aspire Biopharma Holdings | 64.13 Mn | 51.96 Mn | -30,086.00 | 4,766.85% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4,766.85% |
| Mar 31, 2026 | 334.97% |
| Dec 31, 2025 | 27,532.92% |
| Sep 30, 2025 | 11,678.44% |
| Jun 30, 2025 | 1,175.25% |
| Mar 31, 2025 | 2,747.60% |
| Dec 31, 2024 | -67.49% |
| Sep 30, 2024 | -93.38% |
| Jun 30, 2024 | -84.34% |
| Mar 31, 2024 | -85.00% |
| Dec 31, 2023 | -97.75% |
| Sep 30, 2023 | -53.11% |
| Jun 30, 2023 | -78.40% |
| Mar 31, 2023 | -49.01% |